Skip to main content

Medicyte Licenses Life Technologies' Lentiviral Vector Technology

NEW YORK (GenomeWeb News) – German firm Medicyte today said that it has licensed lentiviral vector technology from Life Technologies for use in developing cell-based assays.

Medicyte said that it would incorporate the licensed technology into its Upcyte cell products for the biopharma and academic research markets. Financial and other terms of the alliance were not disclosed.

"With the technology we have licensed from Life Technologies, we are capable to bring more predictive, reliable, and standardized cell strains on the market," Medicyte CEO Joris Braspenning said in a statement.

Medicyte's Upcyte technology is used to proliferate primary cells, which are used in cell-based assays for research, screening, and drug development.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.